关于停药的相关内容

摘要：这3名患者在取得稳定的分子学缓解之后（融合基因转阴PCRU）停用达沙替尼。1名患者复发，另外两名患者在1年后仍保持了PCRU。以前说过，达沙替尼确实可以提高免疫力，希望今后能获得更多的相关研究报告。
' y) B- q9 W& Y: \    关于这个研究值得注意的是，这三名患者都是服用格列卫失败后转用达沙替尼的，也即他们对格列卫是耐药的。这与法国的格列卫停药研究又有所不同，那个研究中的患者都是对格列卫反应良好的。希望医生们能扩大研究长期观察，看看停用达沙替尼是否能持久不复发。
9 N: t/ N3 C. n" U+ K/ ~, n4 G5 I
作者：来自澳大利亚
% D0 H) ]4 [1 v% @来源：Haematologica. 2011.8.9.
Dear Group,
: D$ {6 W, Z) L8 Y* H, F
9 k& u# {$ D+ j$ U4 r5 Z4 XSome of you are on Dasatinib (Sprycel) and we wish to give news on all CML
4 v  R' }! z+ V" L/ qtherapies. Here is a report from Australia on 3 patients who went off Sprycel
( C9 Z% M- {- |after stable molecular response (PCRU). 1 patient relapsed but 2/3 patients
remain in stable PCRU at the 1 year mark. Some of you may remember that Sprycel
does spike up the immune system so I hope more reports come out on this issue.

The remarkable news about Sprycel cessation is that all 3 patients had failed
Gleevec and Sprycel was their second TKI so they had resistant disease. This is
! M1 _0 {9 l& l' d2 }" w/ jdifferent from the stopping Gleevec trial in France which only targets patients
4 ^- @3 ^2 Q" Rwho have done well on Gleevec.
7 R. ~. A6 t* l
Hopefully, the doctors will report on a larger study and long-term to see if the
( ^+ ?+ M* J2 m5 ]8 gresponse off Sprycel is sustained.
. \2 d3 [# D- Y, G2 T- N
Best Wishes,
2 @$ y! i. s8 LAnjana

. Y; v9 f# k; E' G& V3 y

: O7 T1 x- y4 z3 Z& J6 RHaematologica. 2011 Aug 9. [Epub ahead of print]
Durable complete molecular remission of chronic myeloid leukemia following
# I0 o, @& _- Z# T2 ldasatinib cessation, despite adverse disease features.
; g. C" R9 V3 f9 VRoss DM, Bartley PA, Goyne J, Morley AA, Seymour JF, Grigg AP.
Source
4 o2 h: r+ {1 k- nAdelaide, Australia;

Abstract
' z9 v- Q5 P2 x+ S: P0 q7 ?/ kPatients with chronic myeloid leukemia, treated with imatinib, who have a
durable complete molecular response might remain in CMR after stopping
, D6 M' Y" ~7 Ttreatment. Previous reports of patients stopping treatment in complete molecular
9 {3 m+ ]) D8 @response have included only patients with a good response to imatinib. We
1 U8 ?/ H8 a! n' b% Bdescribe three patients with stable complete molecular response on dasatinib
treatment following imatinib failure. Two of the three patients remain in
4 M/ `' b+ B, c; {4 T5 Ocomplete molecular response more than 12 months after stopping dasatinib. In
these two patients we used highly sensitive patient-specific BCR-ABL1 DNA PCR to
show that the leukemic clone remains detectable, as we have previously shown in
$ a" T0 f; J( A2 B# |imatinib-treated patients. Dasatinib-associated immunological phenomena, such as
the emergence of clonal T cell populations, were observed both in one patient
who relapsed and in one patient in remission. Our results suggest that the
; Q8 N9 Q, L, `* `. M6 @characteristics of complete molecular response on dasatinib treatment may be
similar to that achieved with imatinib, at least in patients with adverse
% p0 o' a% T9 Wdisease features.
, ^  U& w2 \5 I7 J& @5 ]% p4 z- N

摘要：（STIM试验为法国的格列卫停药试验。）这个研究中，患者先是取得了CMR（融合基因转阴），然后停用格列卫，而后复发。15名复发患者在重新服药后又一次取得了CMR，他们同意再次停药。
    第一次CMR持续时间为31个月，然后患者停药，复发的中位时间为2.6个月，然后重新服用格列卫，中位时间5.3个月之后取得第二次CMR。保持第二次CMR中位时间19个月之后，患者同意再次停药，这次，15名患者中有5名在停药随访中位时间24个月后仍然保持了CMR，而10名患者在停药中位时间2月后第二次复发。
1 e' y6 q5 J( [  c+ O* N0 s( w    请注意，这些患者都是在第一次CMR后停药然后又复发的患者。
% ~2 s  `0 ^4 v. v. A+ t6 z  U! ~
& E# f+ L! }" u作者：来自法国STIM试验
- @8 _: y7 b: J" c来源：EHA 2011.6.会议摘要

很不错的文章，看来马老师家有考虑停药的想法了啊！祝福！

期盼易或特也能停药，但现在觉得是一个梦想！

这个非常有意义的研究。能吃下来停会再吃，再停，那是天大的好事